Goldman Sachs’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.08M | Buy |
299,657
+41,049
| +16% | +$148K | ﹤0.01% | 3792 |
|
|
2025
Q1 | $773K | Sell |
258,608
-53,527
| -17% | -$160K | ﹤0.01% | 3987 |
|
|
2024
Q4 | $1.05M | Buy |
312,135
+11,207
| +4% | +$37.5K | ﹤0.01% | 3893 |
|
|
2024
Q3 | $1.01M | Buy |
300,928
+79,586
| +36% | +$267K | ﹤0.01% | 3750 |
|
|
2024
Q2 | $733K | Buy |
221,342
+14,273
| +7% | +$47.2K | ﹤0.01% | 3751 |
|
|
2024
Q1 | $837K | Sell |
207,069
-21,771
| -10% | -$88K | ﹤0.01% | 3720 |
|
|
2023
Q4 | $698K | Sell |
228,840
-32,183
| -12% | -$98.2K | ﹤0.01% | 3783 |
|
|
2023
Q3 | $783K | Sell |
261,023
-44,698
| -15% | -$134K | ﹤0.01% | 3664 |
|
|
2023
Q2 | $1.14M | Buy |
305,721
+25,661
| +9% | +$96K | ﹤0.01% | 3541 |
|
|
2023
Q1 | $938K | Buy |
280,060
+36,843
| +15% | +$123K | ﹤0.01% | 3694 |
|
|
2022
Q4 | $1.17M | Buy |
243,217
+2,833
| +1% | +$13.6K | ﹤0.01% | 3606 |
|
|
2022
Q3 | $1.37M | Buy |
240,384
+13,164
| +6% | +$74.9K | ﹤0.01% | 3642 |
|
|
2022
Q2 | $1.61M | Buy |
227,220
+25,527
| +13% | +$181K | ﹤0.01% | 3605 |
|
|
2022
Q1 | $1.46M | Sell |
201,693
-77,875
| -28% | -$562K | ﹤0.01% | 3828 |
|
|
2021
Q4 | $2.5M | Sell |
279,568
-433,657
| -61% | -$3.88M | ﹤0.01% | 3333 |
|
|
2021
Q3 | $25M | Buy |
713,225
+333,001
| +88% | +$11.7M | 0.01% | 1576 |
|
|
2021
Q2 | $8.17M | Buy |
380,224
+126,036
| +50% | +$2.71M | ﹤0.01% | 2403 |
|
|
2021
Q1 | $15.7M | Buy |
254,188
+10,547
| +4% | +$651K | ﹤0.01% | 1854 |
|
|
2020
Q4 | $10.2M | Buy |
+243,641
| New | +$10.2M | ﹤0.01% | 2043 |
|